Eisai Alzheimer’s Drug to Get Medicare Coverage on Full FDA Nod

New Alzheimer’s drugs like Eisai Co.’s Leqembi will be covered by the US Medicare program as soon as they receive full regulatory approval, government health officials said.

Eisai’s drug, one of the first in a new class that removes a toxic protein called amyloid from the brain’s of Alzheimer’s patients, received accelerated approval in January and is under review for full approval from the Food and Drug Administration. Medicare, which provides health coverage for elderly Americans, doesn’t currently cover the drug because of a controversial policy that calls for full US approval.

Medicare has been under pressure ...